Tags

Type your tag names separated by a space and hit enter

Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
J Ocul Pharmacol Ther. 2012 Oct; 28(5):547-9.JO

Abstract

PURPOSE

To report a case of worsening of vitreomacular traction (VMT) after the dexamethasone intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).

CASE

A 71-year-old man who presented with macular edema secondary to CRVO was treated by intravitreal injections of bevacizumab followed by Ozurdex.

RESULTS

VMT developed during the course of treatment and became more evident when macular edema resolved after treatment with Ozurdex.

CONCLUSION

VMT may become apparent and worsen after resolution of macular edema treated with intravitreal Ozurdex.

Authors+Show Affiliations

Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA. bakri.sophie@mayo.eduNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22537269

Citation

Bakri, Sophie J., and Ahmed F. Omar. "Evolution of Vitreomacular Traction Following the Use of the Dexamethasone Intravitreal Implant (Ozurdex) in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion." Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 28, no. 5, 2012, pp. 547-9.
Bakri SJ, Omar AF. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther. 2012;28(5):547-9.
Bakri, S. J., & Omar, A. F. (2012). Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, 28(5), 547-9.
Bakri SJ, Omar AF. Evolution of Vitreomacular Traction Following the Use of the Dexamethasone Intravitreal Implant (Ozurdex) in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion. J Ocul Pharmacol Ther. 2012;28(5):547-9. PubMed PMID: 22537269.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. AU - Bakri,Sophie J, AU - Omar,Ahmed F, Y1 - 2012/04/26/ PY - 2012/4/28/entrez PY - 2012/4/28/pubmed PY - 2013/2/12/medline SP - 547 EP - 9 JF - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JO - J Ocul Pharmacol Ther VL - 28 IS - 5 N2 - PURPOSE: To report a case of worsening of vitreomacular traction (VMT) after the dexamethasone intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). CASE: A 71-year-old man who presented with macular edema secondary to CRVO was treated by intravitreal injections of bevacizumab followed by Ozurdex. RESULTS: VMT developed during the course of treatment and became more evident when macular edema resolved after treatment with Ozurdex. CONCLUSION: VMT may become apparent and worsen after resolution of macular edema treated with intravitreal Ozurdex. SN - 1557-7732 UR - https://www.unboundmedicine.com/medline/citation/22537269/Evolution_of_vitreomacular_traction_following_the_use_of_the_dexamethasone_intravitreal_implant__Ozurdex__in_the_treatment_of_macular_edema_secondary_to_central_retinal_vein_occlusion_ L2 - https://www.liebertpub.com/doi/10.1089/jop.2011.0184?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -